Australian medicines regulator, the Therapeutic Goods Administration (TGA), has granted approval for mRESVIA (mRNA-1345), an ...
CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian ...
Total company revenue fell from a peak of $19.3 billion in 2022 to $3.2 billion for the full year ended Dec. 31, 2024. For ...
Researchers at the University of Cologne have found that mRNA-based COVID-19 vaccines have a lasting impact on the innate ...
Given the uncertainty around its top-line growth, short-term investors should exercise caution when investing in MRNA stock.
Vietnam Investment Review on MSN1d
AIM Vaccine Cuts 2024 Losses by 90%, Paving the Way for Breakthrough GrowthAIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published its 2024 Annual Results announcement on March 30, ...
Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...
AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published its 2024 Annual Results announcement on March 30, 2025, the company recorded revenues of RMB 1,285 million in 2024, an ...
Vietnam Investment Review on MSN7d
AIM Vaccine's mRNA Shingles Vaccine Approved by the US FDA to Begin Clinical Trials, AI-Enabled mRNA Major Vaccine Product Development Acceleratesthe mRNA shingles vaccine and the mRNA RSV vaccine. In just one month, AIM has leveraged its independently innovated mRNA technology platform to deliver two major products, both of which have received ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback